Analisis Efektivitas Biaya Penggunaan Antara Metformin dan Glimepiride Pada Penderita Diabetes Melitus Tipe 2 Rawat Jalan di Rumah Sakit PKU Muhammadiyah Delanggu 2016

In 2013 diabetes has caused 5.1 million deaths worldwide. Indonesia ranked 7th of 10 countries with the highest diabetics in 2013. In 2011 the cost of DM therapy reached USD 465 billion, and expected to increase by USD 595 billion in 2030. The aim of this study to know about the most cost effective oral antidiabetic between metformin or glimepiride in outpatient with type 2 diabetes at PKU Muhammadiyah Delanggu Hospital in 2016. Data of this research is medical record data which taken by retrospective without giving intervention with the number of sample 28 that fulfill inclusion criteria, the type of this research is non experimental research with purposive sampling technique. Cost effectiveness analysis can be done by calculating direct medical cost, effectiveness therapy, and calculation with ACER and ICER method. Based on the results of this research about analysis cost-effectiveness of antidiabetic therapy in outpatients with type 2 diabetes in PKU Muhammadiyah Hospital Delanggu 2016 which has been done by researchers can be concluded that antidiabetic that used is metformin as many as 20 cases (71,43%) and glimepidiride as many as 8 cases (28 , 57%). The most cost-effective antidiabetic therapy based on value of ACER is a glimepiride with an ACER value of Rp 691.553,600 and ICER Rp 20.771,829